Rediff Logo
 Money
Line
Channels: Astrology | Broadband | Contests | E-cards | Money | Movies | Romance | Search | Women
Partner Channels: Bill Pay | Health | IT Education | Jobs | Travel
Line
Home > Money > Reuters > Report
August 29, 2001 		Feedback  
  Money Matters

 -  Business Special
 -  Business Headlines
 -  Corporate Headlines
 -  Columns
 -  IPO Center
 -  Message Boards
 -  Mutual Funds
 -  Personal Finance
 -  Stocks
 -  Tutorials
 -  Search rediff

    
      

 
Reuters
 Search the Internet
         Tips
 Sites: Finance, Investment
E-Mail this report to a friend
Print this page

Dr Reddy's files for generic Zofran in US

Drugmaker Dr Reddy's Laboratories said it has filed for US marketing approvals for three forms of the generic version of GlaxoSmithKline Plc's Zofran drug.

It said in a statement released late on Tuesday an application had been filed with the US Food and Drug Administration for marketing ondansetron in the 4 mg, 8 mg and 24 mg dosage form.

Ondansetron is the main chemical ingredient in the anti-emetic Zofran.

The New York Stock Exchange-listed Dr Reddy's said that GlaxoSmithKline has filed a lawsuit against the company alleging patent infringement.

"Dr Reddy's believes that it has the first to file status for all the three strengths and if successful in its litigation, would enjoy a 180-day exclusivity on the product," the company said.

On the NYSE the company's American Depositary Receipts fell 0.76 per cent to $23.42 on Tuesday.

Two ADRs equal one Indian-listed share.

Back to top
(c) Copyright 2000 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Tell us what you think of this report

ADVERTISEMENT